Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02614508 · Emory University · PHASE1 · terminated · last registry update 2019-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-18Results posted on the registry: Novartis Pharmaceuticals, Fulvestrant + BKM120 (NCT01610284)
- 2020-05-07Results posted on the registry: Vanderbilt-Ingram Cancer Center, Enzalutamide + Taselisib (NCT02457910)
- 2020-04-28Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Hydroxychloroquine (HCQ) + Gedatolisib (NCT03400254)
- 2020-04-08Phase 3 first posted: Adlai Nortye Biopharma Co., Ltd., Buparlisib & Paclitaxel (NCT04338399)
- 2019-11-22Also stopped (withdrawn): Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-11-14Results posted on the registry: Novartis Pharmaceuticals, BKM120 + Trastuzumab (NCT01816594)
- 2019-10-25Phase 3 first posted: Restorbio Inc., Dactolisib + Placebo (NCT04139915)
- 2019-10-04Also stopped (terminated): University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-10-03Results posted on the registry: University of Florida, Gedatolisib + Paclitaxel (NCT02920450)
- 2019-08-13Results posted on the registry: Canadian Cancer Trials Group, Buparlisib (NCT02340780)
- 2019-08-01Results posted on the registry: University of Oxford, BKM120 (NCT02128724)
- 2019-06-11Results posted on the registry: Sanofi, SAR245408 + SAR245409 (NCT01587040)
- 2019-05-31Phase 3 first posted: Global Coalition for Adaptive Research, Temozolomide + Lomustine (NCT03970447)
- 2019-04-10Also stopped (terminated): Cliniques universitaires Saint-Luc- Université Catholique de Louvain, BEZ235 (NCT01856101)
- 2019-03-06Results posted on the registry: SWOG Cancer Research Network, Taselisib (NCT02785913)
- 2019-02-05Also stopped (terminated): Dana-Farber Cancer Institute, BKM120 + Abiraterone (NCT01741753)
- 2019-01-30Also stopped (terminated): Novartis Pharmaceuticals, Fulvestrant + BKM120 (NCT01633060)
- 2019-01-29Results posted on the registry: Anne Chang, Buparlisib + Sonidegib (NCT02303041)
- 2019-01-29Also stopped (terminated): Anne Chang, Buparlisib + Sonidegib (NCT02303041)
- 2019-01-25Results posted on the registry: Hoffmann-La Roche, Taselisib + Placebo (NCT02340221)
- 2019-01-23Results posted on the registry: Dana-Farber Cancer Institute, BKM120 (NCT01790932)
- 2019-01-09Results posted on the registry: Novartis Pharmaceuticals, Fulvestrant + BKM120 (NCT01633060)
- 2019-01-08Also stopped (terminated): Pfizer, PF-05212384 + PF-05212384 (NCT01420081)
- 2019-01-08Also stopped (terminated): Pfizer, PF-05212384 + irinotecan (NCT01925274)
- 2018-12-19Results posted on the registry: Patrick Joseph Loehrer Sr., BKM120 (NCT02220855)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision